Optomed Oyj First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St

May 08, 2025

Optomed Oyj (HEL:OPTOMED) First Quarter 2025 Results

Key Financial Results

Revenue: €4.02m (up 21% from 1Q 2024).
Net loss: €1.58m (loss widened by 45% from 1Q 2024).
€0.083 loss per share (further deteriorated from €0.064 loss in 1Q 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

earnings-and-revenue-growth — HLSE:OPTOMED Earnings and Revenue Growth May 8th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Optomed Oyj Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 8.7%. Earnings per share (EPS) missed analyst estimates by 14%.

Looking ahead, revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Finland.

Performance of the Finnish Medical Equipment industry.

The company's shares are up 6.2% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 2 warning signs for Optomed Oyj that you should be aware of.

If you're looking to trade Optomed Oyj, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.